Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Diane Souza and Thomas Südhof

They join the board as independent directors

Sanofi has appointed Diane Souza and Thomas Südhof to its board of directors as independent directors, effective 4 May.

Souza brings over 25 years of managed care and health benefits expertise as well as financial management experience to the board. She most recently served as chief executive officer of UnitedHealthcare Speciality Benefits, a voluntary health insurance business.

Prior to this, Souza held the role of chief financial officer at Aetna, overseeing its guaranteed products business, and has also held senior leadership positions at Deloitte and PriceWaterhouseCooper.

Meanwhile, Südhof currently serves as the Avram Goldstein professor and professor of molecular and cellular physiology, psychiatry and neurology at Stanford University's school of medicine.

Before joining Stanford, he spent 25 years at the University of Texas as chairman of the department of neuroscience researching neuro-degenerative and neuro-psychiatric diseases. Südhof was a member of team who won the Nobel Prize in physiology or medicine in 2013.

Serge Weinberg, chairman of Sanofi's board, said: “Both Diane Souza and Thomas Südhof are noted health experts and their great skills make them an outstanding addition to our board.

“We look forward to their contribution to Sanofi's strategy as we continue to innovate and introduce new medicines and vaccines that can help improve health outcomes.”

22nd March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics